男男性行为者中HIV暴露前预防、性传播感染检测强度与抗生素处方:回顾性队列研究
结果显示,当前PrEP使用者在年检测强度下NG和CT检出率显著高于从未使用者(NG aIRR 4.2,CT aIRR 5.2),但相对差异随检测强度增加而减弱,多西环素、阿奇霉素和头孢曲松处方呈现相似模式。
要点
- 当前PrEP使用与更高的NG和CT检出率相关,年检测强度下aIRR分别为4.2和5.2。
- 检测强度增加可减弱PrEP使用与STI检出之间的相对差异。
- 多西环素、阿奇霉素和头孢曲松处方模式与STI检出相似,头孢氨苄无一致关联。
核心结论
- 在PrEP照护中,检测强度与检出的CT/NG发病率及STI导向抗生素处方强烈相关。
- 应考虑在PrEP项目中评估风险分层检测策略作为抗菌药物管理的一部分。
研究设计与样本
- 回顾性队列研究,使用以色列Maccabi健康服务2019年1月至2024年6月的电子健康记录。
主要发现
- 年检测强度下,当前PrEP使用与更高检出的NG和CT发病率相关(NG aIRR 4.2;95% CI 3.8-5.3;CT aIRR 5.2;95% CI 4.0-6.6)。
- 这些相对差异随检测强度增加而减弱。
- 多西环素、阿奇霉素和头孢曲松处方遵循相似模式,头孢氨苄与PrEP状态或检测强度无一致关联。
关键数值与推荐
- PrEP暴露分类为从未、当前、近期或停止使用,并滞后一个间隔。
- 检测强度定义为每季度STI检测事件数。
- 结局包括阳性PCR结果和门诊多西环素、阿奇霉素、头孢曲松处方;头孢氨苄作为阴性对照。
- 使用混合效应负二项模型估计调整发病率比(aIRR),包括PrEP与检测的交互作用。
临床怎么用
- 在PrEP随访中应关注检测强度对STI检出和抗生素处方的影响。
- 可考虑根据风险分层调整检测频率以平衡STI发现与抗菌药物管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To quantify the joint associations of time-varying HIV pre-exposure prophylaxis (PrEP) exposure and bacterial sexually transmitted infections (STIs) testing intensity on detected Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) incidence, and STI-related antibiotic prescribing among men who have sex with men. METHODS: We conducted a retrospective cohort study using electronic health records from Maccabi Health Care Services, Israel, from January 2019 to June 2024. Men aged ≥21 years with ≥1 rectal CT/NG-PCR test were followed in 3-month intervals. PrEP exposure was classified as never, current, recent, or stopped use and lagged by one interval. Testing intensity was defined as the quarterly number of STI testing events. Outcomes were positive PCR results and outpatient prescriptions for doxycycline, azithromycin and ceftriaxone; cephalexin served as a negative control. Adjusted incidence rate ratios (aIRRs) were estimated using mixed-effects negative binomial models including a PrEP-by-testing interaction. RESULTS: Overall, 6943 men contributed 174 516 person-months; 12 573 person-months (7.2%) included ≥1 positive CT/NG-PCR result. At annual testing intensity, current PrEP use was associated with higher detected NG and CT incidence than never use (NG aIRR 4.2; 95% CI, 3.8-5.3; CT aIRR 5.2; 95% CI, 4.0-6.6). These relative differences attenuated with increasing testing intensity. Doxycycline, azithromycin and ceftriaxone prescribing followed similar patterns, whereas cephalexin showed no consistent association with PrEP status or testing intensity. CONCLUSIONS: In PrEP care, testing intensity was strongly associated with detected CT/NG incidence and STI-directed antibiotic prescribing. Risk-stratified testing strategies should be evaluated as part of antimicrobial stewardship in PrEP programmes.
引用
- Atias D, Patalon T, Gazit S, et al. HIV pre-exposure prophylaxis, sexually transmitted infections testing intensity and antibiotic prescribing among men who have sex with men: a retrospective cohort study. Clin Microbiol Infect. 2026. PMID: 42526798. doi:10.1016/j.cmi.2026.07.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。